Abstract | OBJECTIVES: BACKGROUND: When compared with moderate-dose statins, intensive statin therapy reduces MACE among patients with ACS. The role of intensive statin therapy specifically among patients who undergo PCI for ACS is unknown. METHODS: RESULTS: Treatment with 80 mg atorvastatin reduced the incidence of the composite end point (21.5% vs. 26.5%, hazard ratio: 0.78, 95% confidence interval: 0.67 to 0.91, p=0.002) and lowered the incidence of both TVR (11.4% vs. 15.4%, p=0.001) and non-TVR (8.0% vs. 10.5%, p=0.017) compared with 40 mg pravastatin. After adjusting for on-treatment serum low-density lipoprotein cholesterol and C-reactive protein concentrations, the odds of TVR with high-dose statin therapy remained significant (odds ratio: 0.74, p=0.015) while the odds of non-TVR did not (odds ratio: 0.92, p=0.55). CONCLUSIONS:
|
Authors | C Michael Gibson, Yuri B Pride, Claudia P Hochberg, Sarah Sloan, Marc S Sabatine, Christopher P Cannon, TIMI Study Group |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 54
Issue 24
Pg. 2290-5
(Dec 08 2009)
ISSN: 1558-3597 [Electronic] United States |
PMID | 19958964
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pyrroles
- Atorvastatin
- Pravastatin
|
Topics |
- Acute Coronary Syndrome
(complications, therapy)
- Angioplasty, Balloon, Coronary
- Atorvastatin
- Cardiovascular Diseases
(etiology, prevention & control)
- Female
- Heptanoic Acids
(administration & dosage)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage)
- Male
- Middle Aged
- Pravastatin
(administration & dosage)
- Pyrroles
(administration & dosage)
|